


ECUSTEC Newsletter



Issue 8

December 2018

Full Title: Eculizumab in Shiga-toxin producing E.Coli Haemolytic Uraemic Syndrome (ECUSTEC): A Randomised, Double-Blind, Placebo-Controlled Trial

Short Title: The ECUSTEC trial



Welcome to the eighth issue of the ECUSTEC Newsletter!



We are pleased to inform you that **22 patients** have been recruited to the trial! **11 centres** are open to recruitment and **Alder Hey Children's Hospital** are now in their final stages of set-up with **Confirmation of Capacity and Capability** issued on the **3rd December 2018** which is great news! The Trials Team are continuing to contact potential PICs and we are pleased to inform **79 PICs** have now **confirmed Capacity and Capability** with further sites confirming their interest!

The STEC HUS 2018 season is now over, though we are out of season we urge sites to **continue informing** the Trials Team (ECUSTEC@trials.bham.ac.uk) of any **potential patients** you become aware of to assist in accurate screening and reporting on progress of the trial.

Christmas and New Year Arrangements 2018-2019

Please note that the telephone randomisation service at BCTU will be closed from:

1.00pm Friday 21st December 2018 until **9.00am Thursday 3rd January 2019**

The online randomisation service will still be available during this time. The ECUSTEC Trials Office will be closed from **2.00pm Friday 21st December 2018** until **9.00am Thursday 3rd January 2019**.

SAE Reporting Arrangements Christmas and New Year 2018-2019

Please report any **SAEs** to Dr Sally Johnson as soon as possible by email: sally.johnson15@nhs.net.


Design:

Phase II randomised, parallel-group, double blind, placebo-controlled trial.

Aim:

To assess whether Eculizumab (Ecu) reduces the severity of Shiga-toxin producing Escherichia coli Haemolytic Uraemic Syndrome (STEC HUS) in children and young people.

The ECUSTEC trial is supported by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR Partnership



Participating in ECUSTEC

We are pleased to announce we now have **11** centres fully approved to randomise patients into the ECUSTEC trial. The trial will take place in **12** centres across the UK with the assistance of the Clinical Research Network (CRN). Applications are currently in progress from **1** ECUSTEC sites to gain all the necessary permissions to allow the trial to begin at each site. The table below shows the ECUSTEC sites that were included in the initial IRAS applications.

Alder Hey Children's Hospital	Leeds General Infirmary *
Birmingham Children's Hospital *	Nottingham Children's Hospital *
Bristol Royal Hospital for Children *	Royal Hospital for Children, Glasgow *
Evelina London Children's Hospital*	Royal Manchester Children's Hospital*
Great North Children's Hospital *	Southampton Children's Hospital *
Great Ormond Street Hospital *	University Hospital of Wales*

* Site opened to recruitment



Notices to Investigators!

Maintaining the Double-Blind

To ensure the trial answers the research question as reliably as possible, please could we remind **all site pharmacies** and **unblinded trial staff** to maintain the double-blind and **be aware** of areas where **potential unblinding** may occur i.e. financial monthly reports, informing site or trials unit staff about IMP orders.

Training for New Staff working on ECUSTEC


Local Changes to Research Staff at Approved Centres: If there are any **changes** in **staff** at your site please remember to send us your **updated delegation log**. If new staff are added to the delegation log, please also forward a copy of their **CV** (signed and dated within the last 12 months) and their latest **GCP certificate**. If any new or existing staff would like to arrange one-to-one training about the trial, **please contact Emma Barsoum**. The ECUSTEC team are always happy to help so please contact us if you have any questions!

Patient Identification Centres


Thank you to all of the teams at **ECUSTEC PICs** for supporting and facilitating recruitment into ECUSTEC. If you are aware of any colleagues at secondary care centres who are interested in participating as an ECUSTEC PIC please forward their contact details to the Trials Team (ECUSTEC@trials.bham.ac.uk).

The graph below shows recruitment by month against current targets:

ECUSTEC Actual Recruitment of Sites and Participants



ECUSTEC Projected and Actual Recruitment of Participants to Dec 2018



CRF and Data Management Notices

Case Report Form (CRF) V2.0

The ECUSTEC CRFs have now been updated and were rolled out on the 26th November 2018, all recruiting sites should now be using the updated version 2.0 of the CRFs. The only form which was not updated was the pregnancy notification form. An email was sent out to all recruiting sites, as well as a posted update pack for their site files with instructions on how to update your site files. The new forms have also been added on the [ECUSTEC website](#).

Case Report Form (CRF) Returns

Please can all sites ensure the Certificates of Vaccinations, CRFs and questionnaires are **completed** and **signed by the PI** as close to the **trial assessment point** as possible and then emailed to BCTU, the Trials Team will then check the forms and send data queries via Data Clarification Form for clarification.

Can I also remind all recruiting sites that the CHU-9D questionnaires are only completed for patients who are 3 and over, and patients under 3 do not need to fill out this questionnaires as the data will not be analysed.

As of 10th December 2018, the trials team were expecting a total of 488 patient reporting documents and we have received 436 of these documents, with only 52 outstanding (15 of which are the stool result forms which we are experiencing difficulties in getting the results from PHE). The overall return rate for **all trial reporting documents is 89%**, this is great and **thank you** to all the site staff for helping to achieve this.

Data Clarification Forms (DCFs)

Data queries will be forwarded via a DCF, please ensure these are carefully completed and **signed** off by the **PI** in order for all outstanding queries to be **resolved** in a timely manner.

As of 10th Dec 2018 the trials team have issued 129 DCF forms and we have responses and resolution to 116 of these which is **90%**, so thanks you all for responding to these queries.



ECUSTEC Details:

Trial Sponsor: The Newcastle Upon Tyne Hospitals NHS Foundation Trust

IRAS Project Code: 199217

Funding: National Institute for Health Research Health, Efficacy and Mechanism Evaluation Programme (NIHR EME).

EUDRACT No:
2016-000997-39

CTA: 17136/0282/001-0001

Approval: 3rd January 2017

REC Ref No.: 16/NE/0325 North
East - Newcastle & North Tyneside
1 Research Ethics Committee
Approval: 23rd January 2017

The ECUSTEC trial has been adopted by the NIHR Clinical Research Network (CRN)

ECUSTEC Chief Investigator:

Dr Sally Johnson, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.

Tel: 0191 282 4917

Email: sally.johnson@nuth.nhs.uk

ECUSTEC WEBSITE:

<http://www.birmingham.ac.uk/ECUSTEC>

ECUSTEC FAX: 0121 415 9135

ECUSTEC Tel: 0121 415 9132

ECUSTEC Email: ecustec@trials.bham.ac.uk

POSTAL ADDRESS: ECUSTEC Trial Office, Birmingham Clinical Trials Unit (BCTU), Institute of Applied Health Research, Public Health Building, University of Birmingham, Edgbaston, Birmingham B15 2TT

Thank you for taking the time to read the Christmas ECUSTEC Newsletter!!!

